How do CARs work?: Early insights from recent clinical studies targeting CD19. Academic Article uri icon

Overview

abstract

  • Second-generation chimeric antigen receptors (CARs) are powerful tools to redirect antigen-specific T cells independently of HLA-restriction. Recent clinical studies evaluating CD19-targeted T cells in patients with B-cell malignancies demonstrate the potency of CAR-engineered T cells. With results from 28 subjects enrolled by five centers conducting studies in patients with chronic lymphocytic leukemia (CLL) or lymphoma, some insights into the parameters that determine T-cell function and clinical outcome of CAR-based approaches are emerging. These parameters involve CAR design, T-cell production methods, conditioning chemotherapy as well as patient selection. Here, we discuss the potential relevance of these findings and in particular the interplay between the adoptive transfer of T cells and pre-transfer patient conditioning.

publication date

  • December 1, 2012

Identity

PubMed Central ID

  • PMC3525612

Digital Object Identifier (DOI)

  • 10.1038/icb.1991.58

PubMed ID

  • 23264903

Additional Document Info

volume

  • 1

issue

  • 9